Gemcitabine Plus Oxaliplatin in Advanced Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
Status:
Unknown status
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
Oxaliplatin is a diaminocyclohexane platinum compound, with a mechanism of action similar to
that of cisplatin. Oxaliplatin has a more manageable toxicity profile than cisplatin, with no
renal toxicity and a lower incidence of hematological and gastrointestinal toxicities.
Gemcitabine and oxaliplatin are both active in NSCLC with no overlapping toxicity.
Preclinical studies show a synergistic effect of the gemcitabine-oxaliplatin combination. The
combination of gemcitabine-oxaliplatin is attractive in NSCLC patients as it may improve the
therapeutic index.